Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

Researchers have found that semaglutide may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).

These include commonly prescribed drugs such as Ozempic or Wegovy (semaglutide), Saxenda (liraglutide), Zepbound (tirzepatide ...

Over the last year, weight loss medications such as GLP-1s (such as compounded semaglutide, Ozempic or Wegovy) have become ...

Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

In the same week that Eli Lilly filed three lawsuits against online vendors and wellness spas making compounded versions of ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

A common diabetes and weight-loss drug may also reduce the risk of Alzheimer’s disease, according to a new study. American ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...